Ch 2: INTRODUCTION TO CORPORATE ACCOUNTING — V2: Applied Practical Scenarios & Financial Computations
CS Executive
📚 Corporate Accounting & Financial Management
📖 Ch.2 — INTRODUCTION TO CORPORATE ACCOUNTING
📘 V2: Study Material & Test Yourself
⚡ Free Mode (Answers Locked)
⏱ Duration: 90 Mins
🎯 Total Marks: 50
Passed at: 20 Marks
Max Attempts: 10
⚖️ Statutory Applicability: Applicable for ICSI CS Executive Examinations (December 2026 Attempt - Syllabus 2022)
Exhaustive ICSI CS Executive Test Series with 4-Tier Rubrics, Statutory Analysis, and Real-world Corporate Problem Scenarios.
📑 Exam Questions
5 Questions • Total 50 MarksQuestion 1: Schedule III Division I / II Balance Sheet presentation: Classification of Current vs Non-Current Assets/Liabilities.
10 Marks
📌 Companies (Amendment) Act and Ind AS Presentation Guidance under Schedule III Division II
M/s Kalinga Pharma Limited is finalising its Balance Sheet as at 31st March 2024 as per Schedule III (Division II) of the Companies Act, 2013, applicable to companies complying with Indian Accounting Standards (Ind AS). The Chief Financial Officer (CFO) has placed the following extracts of ledger balances and specific operational notes before you, seeking exact classification of items into Current and Non-Current categories for the Assets and Liabilities sections. Examine the data and prepare the required classified financial statement extracts along with exhaustive working notes.
| Particulars | Ledger Balance as on 31-03-2024 (₹ in Lakhs) |
|---|---|
| 1. Long-term Borrowings (Term Loan from SBI, maturing in tranches up to 31-03-2029) | 4,500.00 |
| 2. Current maturities of Long-term Borrowings (SBI Term Loan due in FY 2024-25) | 900.00 |
| 3. Trade Payables (Including overdue amount of ₹120 Lakhs due to Micro and Small Enterprises outstanding for more than 45 days) | 1,800.00 |
| 4. Short-term Provisions (Includes Provision for Warranties of ₹150 Lakhs expected to be settled in 18 months, and Provision for Leave Encashment of ₹80 Lakhs payable in 10 months) | 230.00 |
| 5. Property, Plant and Equipment (Gross Block ₹8,000 Lakhs less Accumulated Depreciation ₹2,400 Lakhs) | 5,600.00 |
| 6. Intangible Assets under Development (Projected completion in 14 months) | 750.00 |
| 7. Inventories (Includes Raw Materials ₹600 Lakhs, Work-in-Progress ₹300 Lakhs, and Spares ₹150 Lakhs expected to be consumed over 3 years) | 1,050.00 |
| 8. Trade Receivables (Considered Good ₹1,200 Lakhs; Considered Doubtful ₹200 Lakhs less Allowance for Bad Debts ₹200 Lakhs) | 1,200.00 |
| 9. Cash and Cash Equivalents (Balances with banks in current accounts ₹450 Lakhs, Fixed Deposits with maturity of 90 days or less ₹300 Lakhs) | 750.00 |
| 10. Other Bank Balances (Fixed Deposits held as margin money against bank guarantees maturing in 24 months) | 600.00 |
| 11. Short-term Loans and Advances (Loans given to subsidiary companies repayable on demand) | 500.00 |
Additional Information:
1. The company defaulted on the repayment of an interest installment of ₹50 Lakhs due on 15th March 2024 to SBI, which remains unpaid as on 31st March 2024. Consequently, the lender has the unconditional right to recall the entire term loan facility.
2. Out of the total Trade Payables, ₹300 Lakhs represents disputed dues in arbitration with suppliers, with no definite settlement timeline.
3. Inventories include obsolete raw materials costing ₹80 Lakhs which have no net realizable value.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 2: Statement of Profit and Loss structure: Revenue from operations, other income, finance costs.
10 Marks
📌 Schedule III disclosures as amended by MCA notifications regarding trade payables aging, MSME dues, and reclassifications.
M/s Kalinga Pharmaceuticals Limited presents the following extracts from its Trial Balance as at 31st March, 2024. You are required to prepare the Statement of Profit and Loss (Extracts showing Revenue from Operations, Other Income, and Finance Costs) for the year ended 31st March, 2024, in accordance with Schedule III to the Companies Act, 2013, along with detailed Notes to Accounts and Working Notes.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 3: Disclosures required for Share Capital and Reserves & Surplus under Schedule III.
10 Marks
📌 Companies (Accounting Standards) Rules read with Schedule III Division I disclosures and AS-4 (Revised) treatment of proposed dividends.
M/s Kalinga Technologies Limited presents the following extract of Share Capital and Reserves & Surplus from its trial balance as at 31st March, 2024. You are required to prepare the Notes to Accounts for Share Capital and Reserves & Surplus in compliance with Division I of Schedule III to the Companies Act, 2013, incorporating all necessary disclosures and adjustments mentioned below.
### Table 1: Trial Balance Extract of M/s Kalinga Technologies Limited as at 31st March, 2024
| Particulars | Debit (₹ in Lakhs) | Credit (₹ in Lakhs) |
| :--- | :--- | :--- |
| Equity Share Capital (Equity Shares of ₹ 10 each, fully paid) | - | 5,000.00 |
| 9% Preference Share Capital (Preference Shares of ₹ 100 each, fully paid) | - | 2,000.00 |
| Calls-in-Arrears (on 50,000 Equity Shares) | 2.50 | - |
| Capital Reserve (includes ₹ 50 Lakhs from profit on sale of fixed assets) | - | 350.00 |
| Capital Redemption Reserve | - | 500.00 |
| Securities Premium | - | 1,200.00 |
| General Reserve | - | 2,500.00 |
| Surplus i.e., Balance in Statement of Profit & Loss (Opening Credit Balance) | - | 800.00 |
| Profit for the year 2023-24 (before appropriations) | - | 1,450.00 |
| Debenture Redemption Reserve | - | 400.00 |
| Revaluation Reserve | - | 300.00 |
| Shares Forfeited Account (amount originally paid up on 1,00,000 forfeited shares) | - | 40.00 |
### Additional Information & Adjustments:
1. Out of the total Equity Share Capital, 1,00,000 equity shares were issued pursuant to a contract without payment being received in cash.
2. The company bought back and extinguished 2,00,000 of its own equity shares during the year out of free reserves, utilizing Securities Premium to the extent of ₹ 200 Lakhs for premium on buy-back (not yet adjusted in the above trial balance).
3. Board of Directors proposed a final equity dividend of 10% on 31st March, 2024.
4. Transfer to General Reserve out of current year's profit is proposed at ₹ 150 Lakhs.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 4: Comprehensive review of key exam provisions of INTRODUCTION TO CORPORATE ACCOUNTING (Part 4)
10 Marks
📌 Companies (Amendment) Act and Schedule III disclosures regarding current and non-current classification.
M/s Kalinga Pharma Limited presents its Draft Trial Balance and explanatory notes as of 31st March 2024. As the Corporate Accountant, you are required to pass necessary journal entries, prepare the Statement of Profit and Loss (Extracts), and Balance Sheet (Extracts) in accordance with Schedule III of the Companies Act, 2013, incorporating all adjustments.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 5: Comprehensive review of key exam provisions of INTRODUCTION TO CORPORATE ACCOUNTING (Part 5)
10 Marks
📌 Compliance with Schedule III Division I / II of the Companies Act, 2013 and Accounting Standards notified under Section 133.
M/s Kalinga Industries Limited presented a Trial Balance and additional adjustments concerning the preparation of its Balance Sheet and Statement of Profit and Loss as per Schedule III to the Companies Act, 2013. You are required to prepare the Balance Sheet Extract and Statement of Profit and Loss Extract along with exhaustive Working Notes.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Advertisement